Drug-Eluting Balloons

This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.

News | Drug-Eluting Balloons

February 7, 2018 — Medtronic plc recently added to its body of clinical evidence supporting the In.Pact Admiral drug ...

Home February 07, 2018
Home
The B. Braun Sequent Please drug-eluting balloon.
Feature | Drug-Eluting Balloons

November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug ...

Home November 02, 2017
Home
News | Drug-Eluting Balloons

September 18, 2017 — Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU ...

Home September 18, 2017
Home
News | Peripheral Artery Disease (PAD)

September 13, 2017 — Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference ...

Home September 13, 2017
Home
News | Drug-Eluting Balloons

September 13, 2017 — Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from ...

Home September 13, 2017
Home
Technology | Drug-Eluting Balloons

August 29, 2017 — C.R. Bard Inc. announced the Lutonix 035 Drug Coated Balloon PTA Catheter (DCB) has been granted ...

Home August 29, 2017
Home
News | Drug-Eluting Balloons

August 15, 2017 — Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and ...

Home August 15, 2017
Home
Technology | Drug-Eluting Balloons

July 26, 2017 — The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval ...

Home July 26, 2017
Home
Philips acquires purchases Spectranetics
Feature | Cardiovascular Business

June 28, 2017 — Philips Healthcare and Spectranetics Corp. announced they have entered into a definitive merger ...

Home June 28, 2017
Home
News

June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study of ...

Home June 12, 2017
Home
News | Drug-Eluting Balloons

April 26, 2017 — Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA Ball ...

Home April 26, 2017
Home
News | Peripheral Artery Disease (PAD)

March 9, 2017 — Medtronic plc announced the launch of the IN.PACT BTK study to evaluate the effectiveness of a drug ...

Home March 09, 2017
Home
News | Drug-Eluting Balloons

February 8, 2017 — Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and ...

Home February 08, 2017
Home
News | Drug-Eluting Balloons

December 6, 2016 — The Spectranetics Corp. announced in late November that its Stellarex 0.014-inch drug-coated ...

Home December 06, 2016
Home
Technology | Drug-Eluting Balloons

September 26, 2016 — C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational ...

Home September 26, 2016
Home
Subscribe Now